Bone Density Loss: The Most Alarming Long-Term Risk Here's the data that should make every woman on GLP-1 medications pay attention: A 2024 randomized controlled trial found that 52 weeks of semaglutide reduced hip bone density by 2.6% and lumbar spine density by 2.1% compared to placebo The FDA issued a warning for Wegovy, noting increased hip and pelvis fractures in female patients : 1% on Wegovy vs
However, you should reach out to your provider if you experience severe insomnia (sleeping fewer than 4 hours nightly), worsening mood or anxiety alongside sleep loss, daytime impairment from fatigue, or sleep problems that persist beyond one month despite sleep hygiene efforts
It can be caused by Ozempic, any other injection, or any rapid weight loss method at all
But now, the tide is turning
Like all dietary supplements in the United States, Replenza is not FDA approved
In particular, a peptide inhibitor of JNK kinase-mediated mitochondrial cell death pathway, D-JNKI-1 peptide, has shown promises in protecting the cochlea against noise-induced and aminoglycoside induced HC loss when delivered directly into the scala tympani or locally to the round window membrane (Wang et al., 2003b, 2007
01185-6/asset/2164201a-96aa-45fd-b531-5fbac7f670fe/main.assets/gr2.jpg)
